Summary

ADH1B rs1229984 (Arg48His) determines how fast you convert ethanol to acetaldehyde — the His48 "superactive" variant produces a ~40-100x faster enzyme that creates a rapid burst of acetaldehyde after drinking, causing discomfort that protects against alcohol dependence (OR ~0.2-0.4 for alcoholism) but also increases carcinogenic exposure per drinking episode, especially when combined with ALDH2 deficiency.

Genotype spectrum

CC (Arg48/Arg48, ADH1B*1/*1)

Your alcohol metabolism proceeds at a standard rate. No rapid acetaldehyde spike to cause immediate discomfort.

CT (Arg48/His48, ADH1B*1/*2)

You carry partial genetic protection against alcohol overconsumption. The intermediate acetaldehyde spike after drinking creates mild but real discomfort that discourages heavy drinking.

TT (His48/His48, ADH1B*2/*2)

You have the strongest genetic protection against alcohol overconsumption. Your enzyme processes ethanol so rapidly that acetaldehyde accumulates quickly, creating an unpleasant experience that strongly discourages heavy drinking.

Practical takeaway

For CC Carriers (Standard ADH1B)

Awareness value:
• You don't carry the genetic aversion to alcohol that His48 carriers have. Alcohol consumption regulation depends on conscious decisions, social context, and other psychological/genetic factors.
• If family history includes alcohol use disorder: be aware that you lack this specific protective factor. Mindful drinking practices, setting limits, and monitoring consumption patterns are more important for you.
• Check your ALDH2 status — the combination matters more than either gene alone.
For CT Carriers (Intermediate Fast)

Understanding the aversion signal:
• The mild discomfort you may experience after drinking (warmth, flushing, mild nausea) is acetaldehyde accumulation. It's your body's signal proportionate to the toxin level.
• Respect it. The protective effect against alcohol dependence only works if you don't override the signal with willpower, antihistamines, or social pressure.
• Moderate drinking is biochemically reasonable for CT carriers with normal ALDH2 (GG at rs671).
• If you carry ALDH2*2 (GA at rs671): the cancer risk compound applies. See ALDH2 entry for specific recommendations.
For TT Carriers (Superactive ADH1B)

Strong natural protection:
• Your genetic aversion to heavy drinking is one of the strongest protective factors known in addiction genetics.
• If you drink despite discomfort: you're experiencing higher peak acetaldehyde levels than CC carriers. The cancer risk angle is real, especially if ALDH2 is also impaired.
• If you have normal ALDH2 (GG): the rapid acetaldehyde is quickly cleared. Brief discomfort, brief exposure. Moderate consumption is biochemically acceptable.
• If you have ALDH2*2 (GA/AA): maximum acetaldehyde accumulation. This is the highest-risk genotype combination for alcohol-related cancer. Alcohol avoidance is strongly recommended.

Expected response window: N/A — ADH1B genotype is a fixed metabolic parameter. The protective effect against alcoholism operates lifelong. Cancer risk is proportional to cumulative acetaldehyde exposure.

Evidence detail

What This Gene Does

ADH1B encodes alcohol dehydrogenase 1B, the primary enzyme responsible for the first step of alcohol metabolism: oxidising ethanol to acetaldehyde. ADH1B is highly expressed in the liver but also present in the gastric mucosa and upper aerodigestive tract, where it converts alcohol to acetaldehyde locally — a key factor in alcohol-related cancer at these sites.

The rs1229984 variant (C>T in the coding sequence) causes an amino acid change at position 48: Arg48 (C allele, ADH1B1) to His48 (T allele, ADH1B2). This substitution alters the enzyme's kinetic properties dramatically. His48 ADH1B has approximately 40-100x higher catalytic activity than Arg48 ADH1B (V_max increased, K_m for ethanol similar). The result: carriers of the His48 variant convert ethanol to acetaldehyde far more rapidly.

This rapid conversion matters for two reasons. First, it creates a sudden spike in acetaldehyde levels immediately after drinking — causing unpleasant symptoms (facial warmth, nausea, rapid heartbeat) that discourage continued consumption. This is the mechanism behind the well-replicated protective effect against alcohol dependence. Second, the rapid acetaldehyde burst means higher peak acetaldehyde concentrations per drinking episode, which increases DNA damage and carcinogenic exposure — particularly problematic when combined with ALDH2 deficiency (slow acetaldehyde clearance).

The population distribution is striking: the His48 variant is carried by ~70-90% of East Asian populations but only ~5-10% of European populations. This population difference, combined with the ALDH2 rs671 distribution, creates a distinct alcohol metabolism landscape for East Asian versus European individuals.

Mechanism

Alcohol metabolism step 1 — the ADH1B role:

Ethanol enters the liver (and other tissues) and is oxidised to acetaldehyde by alcohol dehydrogenase. The reaction:

Ethanol + NAD+ → Acetaldehyde + NADH + H+

ADH1B is a dimeric zinc metalloenzyme. The zinc atom in the active site coordinates the ethanol substrate, and the NAD+ cofactor accepts the hydrogen during oxidation. The rate of this reaction determines how quickly acetaldehyde is produced.

What His48 changes:

Position 48 sits near the active site, affecting the enzyme's catalytic loop. The His substitution alters the local electrostatic environment, dramatically increasing the enzyme's turnover rate (V_max). In practical terms:
• Arg48 (CC): Steady ethanol conversion. Acetaldehyde production is gradual. Blood acetaldehyde peaks modestly after drinking.
• His48 (CT/TT): Rapid ethanol conversion. Acetaldehyde is produced in a burst. Blood acetaldehyde peaks much higher and earlier after drinking.

The aversion mechanism:

The acetaldehyde burst from fast ADH1B creates:
1. Vasodilation → facial flushing, warmth
2. Tachycardia → racing heart, palpitations
3. Nausea → gastric discomfort
4. Headache → acetaldehyde crosses the blood-brain barrier

These symptoms occur within minutes of the first drink and are unpleasant enough to discourage continued consumption. Over time, this creates a conditioned aversion — the association between alcohol and discomfort reduces drinking motivation. This is the same pharmacological principle used by disulfiram (Antabuse) therapy for alcoholism — disulfiram inhibits ALDH2, causing acetaldehyde accumulation. ADH1B*2 achieves a milder version of this naturally.

The double-edged sword:

The same rapid acetaldehyde production that protects against alcoholism also means higher peak carcinogenic exposure per drinking episode. This is why the ADH1B-ALDH2 compound matters so much:
• Fast ADH1B + Normal ALDH2: Rapid production, rapid clearance. Brief acetaldehyde spike. Protective against alcoholism. Modest cancer risk increase.
• Fast ADH1B + Deficient ALDH2: Rapid production, slow clearance. Prolonged high acetaldehyde exposure. Maximum carcinogenic exposure per drink. Protective against alcoholism but extremely high cancer risk if drinking pers

ADH1B Alcohol

Summary

Genotype spectrum

Practical takeaway

Evidence detail

Sources (8)